Navigation Links
Study calculates patient time costs associated with cancer care

In 2005, the overall cost of patients' time spent on cancer care was $2.3 billion in the first year after diagnosis, according to a new study in the January 3 issue of the Journal of the National Cancer Institute. The time costs for the 11 cancers studied and for different phases of cancer care varied widely, they write.

Several studies have estimated the direct medical costs of cancer care, but few have attempted to include a patient's time associated with cancer care, such as time spent traveling to and from care, waiting for appointments, and receiving services and treatments, all of which represent time not spent working or pursuing day-to-day activities.

In the new study, Robin Yabroff, Ph.D., of the National Cancer Institute, and colleagues quantified the patient time costs associated with cancer care. They used information from the Surveillance, Epidemiology, and End Results–Medicare database on more than 760,000 patients with 11 different types of cancer and from 1.1 million Medicare enrollees without cancer. Using data from 1995 to 2001, they estimated each patient's time spent at physician and emergency room visits, chemotherapy treatments, radiation therapy, hospitalizations, outpatient surgeries, and imaging procedures. They then estimated how long each patient spent traveling to, waiting for, and receiving care. The net costs were calculated using a dollar value of $15.23 per hour, the median U.S. wage rate in 2002.

During the first 12 months after diagnosis, the average length of time for hospitalization was highest for patients with gastric and ovarian cancers (21.1 and 20.8 days) and shortest for patients with melanoma (2.2 days), prostate cancer (3.8 days) and breast cancer (4.0 days). Compared to similar people without cancer, cancer patients' net time associated with medical care varied, ranging from 17.8 hours for melanoma to 351.3 hours for gastric cancer and 368.1 hours for ovarian cancer. When the researchers applied the dollar costs to time spent on medical care in the first 12 months after diagnosis, they found that net patient time costs were lowest for melanoma ($271) and prostate cancer ($842) and highest for gastric ($5,348) and ovarian ($5,605) cancer.

In the last year of life, hospitalization time was longest for patients with gastric (35.4 days), lung (32.4 days), and ovarian (31.9 days) cancer. Estimates of patients' net time spent on medical care were lowest for melanoma (99.1 hours) and highest for ovarian (485.3 hours), lung (488.3 hours), and gastric (512.2 hours) cancer. They calculated that the net patient time costs during the last year of life ranged from $1,509 for melanoma to $7,799 for gastric, $7,435 for lung, and $7,388 for ovarian cancer. Hospitalizations were the largest component of patient time costs in both the initial year after diagnosis and in the last year of life.

"For 2005, the estimated cost for the initial phase of care alone was approximately $2.3 billion," the authors write. These estimates could be combined with estimates of direct and indirect costs to better understand the overall burden of cancer in the United States, the authors write.

"What we see here is a measure of the patient's burden of commitment--measured in dollars--associated with receiving today's cancer therapy," write Larry G. Kessler, Sc.D., of the U.S. Food and Drug Administration and Scott D. Ramsey, M.D., Ph.D., of the Fred Hutchinson Cancer Research Center in Seattle, in an accompanying editorial. "We hope that policy makers recognize the substantial economic burden of cancer in the United States and that this cost derives from many sources ?."

The editorial writers also note that these calculations do not address the emotional cost cancer patients and their families endure. Even accounting for patient time costs, "we know we have greatly underestimated the true cost of the disease," they write. Nevertheless, Kessler and Ram sey conclude, new treatments that reduce patient time costs should be encouraged, and manufacturers should quantify these benefits and then convey them to patients, providers, and health insurers.


'"/>

Source:Journal of the National Cancer Institute


Related biology news :

1. Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down
2. Emory Study Tests Bone Marrow Stem Cells to Improve Circulation in Legs
3. UCLA Study Shows One-Third of Drug Ads in Medical Journals Do Not Contain References Supporting Medical Claims
4. Study Demonstrates Gene Expression Microarrays are Comparable and Reproducible
5. Study Links Ebola Outbreaks To Animal Carcasses
6. Breakthrough Microarray-based Technology for the Study of Cancer
7. NYU Study Reveals How Brains Immune System Fights Viral Encephalitis
8. Study finds more than one-third of human genome regulated by RNA
9. Leukemia Drug Breakthrough Study In New England Journal Of Medicine
10. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
11. New Study from Affymetrix Laboratories Points to Changing View of How Genome Works
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/26/2016)... Research and Markets has announced ... 2016-2020"  report to their offering.  , ,     (Logo: ... analysts forecast the global multimodal biometrics market to ... period 2016-2020.  Multimodal biometrics is being ... the healthcare, BFSI, transportation, automotive, and government for ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... , ... STACS DNA Inc., the sample tracking software company, today announced that ... joined STACS DNA as a Field Application Specialist. , “I am thrilled that ... of STACS DNA. “In further expanding our capacity as a scientific integrator, Hays brings ...
(Date:6/23/2016)... 23, 2016  Blueprint Bio, a company dedicated to ... medical community, has closed its Series A funding round, ... "We have received a commitment from Forentis ... need to meet our current goals," stated Matthew ... runway to complete validation on the current projects in ...
(Date:6/23/2016)... CA (PRWEB) , ... June 23, 2016 , ... ... software, is exhibiting at the Pennsylvania Convention Center and will showcase its product’s ... conference. ClinCapture will also be presenting a scientific poster on Disrupting Clinical Trials ...
(Date:6/23/2016)...  Amgen (NASDAQ: AMGN ) today announced ... life sciences incubator to accelerate the development of new ... at QB3@953 was created to help high-potential life science ... early stage organizations - access to laboratory infrastructure. ... two "Amgen Golden Ticket" awards, providing each winner with ...
Breaking Biology Technology: